Decode Your
Cancer Genomics Define Your Path.

NGS, ctDNA, PGx, Hereditary Review
Comprehensive review of all genetic panels to identify clinically significant variants.

• TMB & Neoantigen Prediction
  Estimates Tumor Mutational Burden and neoantigen load to predict immunotherapy success.
• Immunotherapy Profiling
  Analysis of PD-L1, MSI, TMB for checkpoint inhibitor eligibility.
• Targeted & Hormonal Therapy Matching
  Links actionable mutations with approved or investigational therapies.
• Resistance Mutation Detection
  Detection of secondary mutations that limit therapy efficacy and suggesting alternatives.
• CAR-T/TIL Readiness
  HLA typing and immunogenicity scoring for suitability in advanced cell therapies.
• Drug Repurposing Insight
  Literature-backed suggestions for off-label or emerging drug uses.
• Pathway Activation Scoring
  Multi-omic scoring to understand which cancer pathways are driving tumor progression.
• AI-powered VUS Reclassification & Alerts
  Ongoing monitoring and reevaluation of Variants of Uncertain Significance.
• Annual Variant Re-evaluation
  Scheduled review of past variants to integrate latest research and trials.

• PGx-based chemo risk planning
  Genetic risk prediction for chemo toxicity (e.g., TPMT, DPYD).
• Radiogenomic compatibility check
  Aligning radiation therapy plans with radiosensitivity markers.
• Therapy line sequencing (1st–4th)
  Roadmap for best treatment order based on resistance evolution.
• Drug–Drug Interaction Modeling
  AI model checks for adverse interactions in polypharmacy settings.
• RT + Sensitizer / IO Recommendations
  Combining radiation with sensitizers or immunotherapy based on profile.
• Post-relapse pivot plans
  Advising new lines of treatment post-resistance or relapse.
• PGx-safe supportive drug use
  Personalized pre-medication planning (e.g., antiemetics, steroids).

• ctDNA/MRD trend monitoring
  Longitudinal analysis of circulating tumor DNA for relapse prediction.
• Theranostic eligibility
  Check for ligands/receptors (e.g., PSMA) for radioligand therapy.
• Survivorship planning
  Creating health maintenance plans based on somatic/germline risk.
• Wearables and digital tools
  Guidance on devices/apps that support treatment adherence and monitoring.

• Dual-format reports
  Separate, customized formats for patients and clinicians.
• Tumor board summaries
  Single-page clinical summaries for MDT or tumor board presentation.
• Annual Re-analysis Add-on
  Keeps your report up-to-date with new science, trials, and drugs.

• Hereditary Cancer Risk Analysis
  BRCA, Lynch, and other syndrome testing and interpretation.
• Cascade Testing Blueprint
  Support for testing and informing family members of shared risk.